OIS Podcast | Ophthalmology's leading Podcast - Novaliq’s Bernhard Günther Reveals Company’s Fateful Start, Promising Future for Dry Eye Treatments

Novaliq’s Bernhard Günther Reveals Company’s Fateful Start, Promising Future for Dry Eye Treatments

04/02/19 • 30 min

OIS Podcast | Ophthalmology's leading Podcast

After entering the ophthalmology industry “by accident,” Bernhard Günther founded Novaliq in 2004 to pursue therapeutic applications for CyclASol, a novel solution used in drug delivery. While Novaliq pursued other therapeutic applications initially, fate once again brought Günther back into ophthalmology. Today, the company is positioned to deliver two new treatments for dry eye disease. In this podcast we’ll cover the company’s origins, its unusual investor, and its move to the US.

Previous Episode

What Impact Will Gene Therapy Deals Have on Patients? Start-Ups? Jay Duker, MD, Can Speak for Both.

We dip into the gene therapy pool one more time, talking with Jay Duker, MD about Luxturna’s impact on ophthalmology. We also discuss how the acquisitions of Spark and Nightstar are benefiting earlier-stage gene therapy start-ups, including his own Hemera Biosciences.

Next Episode

Oyster Point Pharma CEO Jeffrey Nau Highlights Details of the Company’s Recent B Round, Ponders IPO

With more than $100 million raised in venture capital and three late-stage clinical programs, Oyster Point Pharma is getting a lot done in a short amount of time. In this podcast, CEO and president Jeffrey Nau reveals how the company is working so quickly and ponders what the next major milestone might be.